In a rat model of insulin resistance, one-week treatment with the orally active B1R antagonist SSR240612 reversed increased levels of superoxide anion and B1R expression in the aorta through the inhibition of NADPH oxidase [62]. Here, FMO5 is linked to Insulin resistance.